

# **Jochen Eimer**

#### **Director**

### **Frankfurt**

T +49 69 1739 2447

## jochen.eimer@squirepb.com

### Languages spoken

English | German



## **About Jochen**

Jochen Eimer is a director in the Corporate Practice based in the Frankfurt office. He focuses his practice on the biotechnology, pharmaceutical and medtech sectors.

Jochen assists national and international clients with mergers and acquisitions, financing and other corporate transactions. He also advises on compliance, anti-corruption and other regulatory matters.

He has particular expertise in the area of agreements for licensing and collaboration, research and development, clinical trials, manufacturing and supply, as well as other industry-specific commercial agreements.

# **Experience**

- Advised an Austrian listed biotech company on the negotiation of a clinical supply agreement with a global biopharma company ancillary to an existing collaboration and licence agreement.\*
- Advised an Austrian listed biotech company on a global licence agreement with a Swiss university.\*
- Advised a German cell therapy company on establishing an intra-group master services and supply agreement and other related agreements.\*
- Advised a Swiss biotech company on a collaboration and licence agreement with a Benelux biotech company involving the algorithm-based identification and selection of patient-individual tumour-specific drug targets.\*
- Advised a Swiss biotech company on a clinical trial collaboration agreement with a Japanese IT company involving the algorithm-based identification and selection of patient-individual tumourspecific drug targets.\*
- Advised a German listed biotech company on the global restructuring of its manufacturing and supply relationships, including the negotiation of a commercial manufacturing and supply agreement with its API supplier, as well as corresponding supply agreements with its third-party licensees.\*
- Advised a German nutraceutical company on its corporate reorganisation, as well as on a global manufacturing and supply agreement with a US customer.\*

- Advised a Polish biotech company on the negotiation of a research collaboration and option agreement, as well as a separate research collaboration and licence agreement with a leading German pharma company.\*
- Advised a Swiss biotech company on a licence and collaboration agreement with an international pharmaceutical company for China and other regions worldwide.\*
- Advised a German listed biotech company on the negotiation of a global licence and codevelopment agreement for its lead compound and various ancillary agreements, including a development supply agreement and a manufacture licence and tech transfer agreement.\*
- Advised an Australian pharma company on the regional amendment of its existing supply agreement with a global pharma company to include certain European territories.\*
- Advised an Austrian listed biotech company on a research collaboration and licence agreement with a US-based cancer medicine company with respect to a certain preclinical discovery programme.\*
- Advised an Austrian listed biotech company on a research collaboration and licence agreement with a global biopharma company.\*
- Advised a leading German pharma company on a cooperation agreement with a world-leading diagnostics company in the area of companion diagnostics.\*
- Advised a German pharma company on a global licence agreement with an Italian pharma company.\*
- Advised a German biotech company on a collaboration with a German research institute.\*
- Advised a Polish biotech company on a global licence agreement with an Italian pharma company.\*
- Advised a German biotech company on a licence and cooperation agreement with a world-leading diagnostics company in the area of companion diagnostics.\*
- Advised a Polish biotech company on the launch of a new biotech company established together with a venture capital firm.\*
- Advised a leading gene therapy company on an exclusive strategic collaboration with a global biopharmaceutical company.\*
- \* Matter handled prior to joining the firm.

## Credentials Education

- London Guildhall University, LL.M., 2002
- Higher Regional Court of Zweibrücken, Second State Examination, 2000
- University of Mainz, First State Examination, 1998

#### **Admissions**

• Germany, 2001

### **Memberships & Affiliations**

• Medical Law Working Group of the German Bar Association

# **Recognitions**

- Recommended as one of the best lawyers for corporate governance and compliance, as well as pharmaceuticals law, in Germany by Handelsblatt (Deutschlands beste Anwälte 2022) and Best Lawyers.
- Recommended by *Handelsblatt Best Lawyers* Ranking *Deutschlands beste Anwälte* 2021 as Lawyer of the Year in Pharmaceuticals Law in Hesse, Germany.
- Recommended by *Leaders League*'s 2019 Guide for Innovation, Technology & Patents, and awarded Excellent in the Health, Pharma & Biotechnology category.
- Recommended in JUVE Handbuch der Wirtschaftskanzleien 2019.
- Recommended as one of the leading lawyers in *The Legal 500 EMEA* 2019.

# **Expertise**

## **Services**

• Corporate

### **Industries**

• Life Sciences

# **About our firm**

One of the world's strongest integrated law firms, providing insight at the point where law, business and government meet. We deliver commercially focused business solutions by combining our legal, lobbying and political capabilities and invaluable connections on the ground to a diverse mix of clients, from long-established leading corporations to emerging businesses, startup visionaries and sovereign nations. More than 1,500 lawyers in over 40 offices across four continents provide unrivaled access to expertise.